Fresh off of a better-than-expected launch with Clostridium difficile-associated diarrhea (CDAD) drug Dificid (fidaxomicin), Cubist Pharmaceuticals Inc. disclosed plans to move into pivotal testing with its own CDAD candidate, CB-183,315, in the first half of next year.